Back to top

Analyst Blog

Cubist Pharmaceuticals Inc. (CBST - Analyst Report) announced the pricing of $700 million of convertible senior notes. The unsecured notes will be issued in two series of $300 million and $400 million (principal amount). The company has provided an over-allotment option to the underwriters for purchasing an additional $50 million worth of notes.

The $300 million notes will carry an annual interest rate of 1.125% and are set to mature on Sep 1, 2018. The $400 million notes will bear an interest rate of 1.875% and are set to mature on Sep 1, 2023. The interest amount will be payable on Sep1 and Mar 1 from Mar 1, 2014 in each case. Cubist Pharma further stated that the notes cannot be redeemed before they mature. Moreover, the notes can be converted into cash, shares of Cubist Pharma’s common stock or a combination of both in certain circumstances/time periods.

Cubist Pharma expects to raise a net amount of $679 million from this transaction. The company intends to make use of the amount primarily to finance its impending acquisition of antibiotics maker Optimer Pharmaceuticals, Inc. . The deal is expected to close by year end.

Following the deal with Optimer Pharma, Cubist Pharma extended its deal with Optimer Pharma (which was scheduled to end in Jul 2013) by up to a year. As per the deal, the companies co-promote Dificid (fidaxomicin) in the U.S. for the treatment of C. difficile acquired diarrhea. Dificid is available in the U.S. since Jul 2011.

Cubist Pharma, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Companies such as Gilead Sciences Inc. (GILD - Analyst Report) and Actelion Ltd. (ALIOF) appear to be more attractive in the biopharma space. Both stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%